Global Newsroom

^{_{CSL Behring Patient Zahra Khan, living with hereditary angioedema}}

Latest News

CSL Seqirus

Feb 15, 2026

neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been...

Dec 7, 2025

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic...

CSL Seqirus

Dec 2, 2025

World-class $1bn vaccine and antivenom manufacturing facility opens in Melbourne

Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,...

Nov 18, 2025

CSL to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies

Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states

CSL Seqirus

Oct 29, 2025

CSL Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic influenza vaccines

Thursday 30 October, Riyadh – CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology...

View All News

Vita: Original Stories

'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.